These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 25274031)
1. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Volk-Draper L; Hall K; Griggs C; Rajput S; Kohio P; DeNardo D; Ran S Cancer Res; 2014 Oct; 74(19):5421-34. PubMed ID: 25274031 [TBL] [Abstract][Full Text] [Related]
2. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. Sootichote R; Thuwajit P; Singsuksawat E; Warnnissorn M; Yenchitsomanus PT; Ithimakin S; Chantharasamee J; Thuwajit C BMC Cancer; 2018 Feb; 18(1):231. PubMed ID: 29486738 [TBL] [Abstract][Full Text] [Related]
3. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Rajput S; Volk-Draper LD; Ran S Mol Cancer Ther; 2013 Aug; 12(8):1676-87. PubMed ID: 23720768 [TBL] [Abstract][Full Text] [Related]
4. The Role of TLR4 in Chemotherapy-Driven Metastasis. Ran S Cancer Res; 2015 Jun; 75(12):2405-10. PubMed ID: 25998620 [TBL] [Abstract][Full Text] [Related]
5. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers. Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322 [TBL] [Abstract][Full Text] [Related]
7. ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients. Rodrigues-Ferreira S; Nehlig A; Kacem M; Nahmias C Sci Rep; 2020 Aug; 10(1):13217. PubMed ID: 32764625 [TBL] [Abstract][Full Text] [Related]
8. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8. Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N Gene; 2021 Aug; 792():145728. PubMed ID: 34022297 [TBL] [Abstract][Full Text] [Related]
9. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338 [TBL] [Abstract][Full Text] [Related]
10. Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling. Sun T; Liu Y; Li M; Yu H; Piao H Mol Cell Probes; 2020 Oct; 53():101602. PubMed ID: 32447047 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241 [TBL] [Abstract][Full Text] [Related]
12. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4. Volk-Draper LD; Hall KL; Wilber AC; Ran S PLoS One; 2017; 12(6):e0179257. PubMed ID: 28598999 [TBL] [Abstract][Full Text] [Related]
13. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration. Liao SJ; Zhou YH; Yuan Y; Li D; Wu FH; Wang Q; Zhu JH; Yan B; Wei JJ; Zhang GM; Feng ZH Breast Cancer Res Treat; 2012 Jun; 133(3):853-63. PubMed ID: 22042369 [TBL] [Abstract][Full Text] [Related]
14. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation. Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733 [TBL] [Abstract][Full Text] [Related]
16. Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. Wu J; Guan M; Wong PF; Yu H; Dong J; Xu J Food Chem Toxicol; 2012 Sep; 50(9):3019-24. PubMed ID: 22743248 [TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. Yang H; Wang B; Wang T; Xu L; He C; Wen H; Yan J; Su H; Zhu X PLoS One; 2014; 9(10):e109980. PubMed ID: 25299052 [TBL] [Abstract][Full Text] [Related]
18. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel in anthracycline-resistant metastatic breast cancer. Hui YF; Ignoffo RJ Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651 [TBL] [Abstract][Full Text] [Related]
20. Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. Jin Y; Hu W; Liu T; Rana U; Aguilera-Barrantes I; Kong A; Kumar SN; Wang B; Gao P; Wang X; Duan Y; Shi A; Song D; Yang M; Li S; Han B; Zhao G; Fan Z; Miao QR Cancer Lett; 2018 Apr; 419():233-244. PubMed ID: 29373839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]